IJIMM, Volume 3, Issue 10, 2025 ISSN: 2995-5319
http://medicaljournals.eu/index.php/IJIMM

INTERNATIONAL JOURNAL OF INTEGRATIVE AND MODERN MEDICINE

Pathophysiological Mechanisms, Clinical Progression, and Emerging Therapeutic Strategies in Diabetic Retinopathy

Xasanova Nargis Qodirovna
Department of Fundamental Medical Sciences of the
Asia International University, Bukhara, Uzbekistan

Abstract: Diabetic retinopathy (DR) is a leading microvascular complication of diabetes mellitus and a major cause of preventable blindness in adults worldwide. It results from chronic hyperglycemia-induced damage to retinal capillaries, leading to vascular leakage, ischemia, and pathological neovascularization. This review aims to summarize the current understanding of the molecular and cellular mechanisms underlying diabetic retinopathy, highlight diagnostic and imaging advances, and discuss emerging therapeutic strategies beyond conventional laser and pharmacologic interventions. Key pathophysiologic mechanisms involve activation of the polyol pathway, accumulation of advanced glycation end-products (AGEs), protein kinase C (PKC) overactivation, and upregulation of vascular endothelial growth factor (VEGF). These processes trigger oxidative stress, inflammation, and neurovascular dysfunction. Recent innovations in imaging such as optical coherence tomography angiography (OCTA) and AI-based screening have improved early detection. Emerging therapies, including anti-VEGF agents, corticosteroid implants, and gene- or cell-based therapies, show promising outcomes. Diabetic retinopathy represents a multifactorial neurovascular disease. Early detection, optimal metabolic control, and individualized multimodal therapy are crucial to prevent irreversible vision loss. Future research should focus on precision medicine approaches integrating biomarkers, genetics, and artificial intelligence.

Keywords: Diabetic retinopathy, vascular pathology, inflammation, retinal degeneration, anti-VEGF, laser treatment, oxidative stress, neurovascular unit.

Introduction

Diabetes mellitus (DM) is one of the most prevalent chronic metabolic diseases, affecting over 540 million adults globally as of 2023. Among its systemic complications, diabetic retinopathy (DR) remains a leading cause of visual impairment and blindness in the working-age population. The World Health Organization (WHO) estimates that approximately one-third of individuals with diabetes develop some form of retinopathy during their lifetime. The risk increases proportionally with the duration of diabetes and the degree of glycemic dysregulation. Diabetic retinopathy is primarily a microvascular complication resulting from chronic hyperglycemia-induced endothelial damage, pericyte loss, and basement membrane thickening. These structural alterations compromise the blood-retinal barrier, resulting in increased vascular permeability, capillary occlusion, and ischemia. Consequently, ischemic retina releases angiogenic factors such as vascular endothelial growth factor (VEGF), leading to pathological neovascularization, which characterizes the proliferative stage of the disease. Beyond vascular dysfunction, recent research emphasizes the role of neurodegeneration and inflammation in the early stages of DR. Retinal neurons and glial cells exhibit metabolic stress long before vascular lesions become clinically evident, supporting the concept of DR as a neurovascular disorder rather than purely a microangiopathy. Clinically, DR is classified into non-proliferative and proliferative stages, with diabetic macular edema (DME) representing the most vision-threatening manifestation at any stage. Major modifiable risk factors include hyperglycemia, hypertension, and dyslipidemia, whereas genetic susceptibility and oxidative stress

serve as non-modifiable contributors. Despite advances in screening and treatment, diabetic retinopathy continues to impose a substantial global burden. The advent of advanced imaging technologies and molecular therapies has revolutionized management, yet the disease's complex pathophysiology necessitates ongoing research to identify more targeted and durable therapeutic approaches.

PATHOPHYSIOLOGY OF DIABETIC RETINOPATHY

Diabetic retinopathy (DR) represents a multifactorial neurovascular complication of diabetes mellitus, arising from the chronic metabolic toxicity of hyperglycemia. The retina, being one of the most metabolically active tissues in the human body, depends critically on fine-tuned glucose and oxygen homeostasis. Persistent hyperglycemia disrupts this equilibrium, initiating a cascade of biochemical, inflammatory, and oxidative events that progressively damage the retinal neurovascular unit (NVU) and compromise the blood–retinal barrier (BRB).

Microvascular Alterations and the Neurovascular Unit

The retinal neurovascular unit—comprising endothelial cells, pericytes, Müller glia, astrocytes, and neurons—maintains the structural and functional integrity of retinal microcirculation. Chronic hyperglycemia triggers mitochondrial oxidative stress and the accumulation of advanced glycation end-products (AGEs), inducing pericyte apoptosis and loss of capillary autoregulation. The ensuing formation of acellular capillaries and microaneurysms constitutes the earliest histopathologic hallmark of DR. Endothelial dysfunction, characterized by the downregulation of tight junction proteins (occludin, claudin-5, and ZO-1), results in BRB breakdown and vascular hyperpermeability. Concurrent Müller cell dysfunction impairs glutamate clearance and potassium buffering, causing neuronal excitotoxicity. Therefore, DR is best conceptualized as a neurovascular degenerative disorder, rather than merely a microangiopathy.

Metabolic pathways in retinal damage

Polyol pathway overactivation : In hyperglycemia, excess intracellular glucose is diverted into the polyol pathway, where aldose reductase reduces glucose to sorbitol at the expense of NADPH. Depletion of NADPH diminishes glutathione (GSH) regeneration, weakening antioxidant defenses. Sorbitol accumulation induces osmotic swelling and pericyte injury, leading to basement membrane thickening and early microvascular dropout.

Advanced glycation end-products (AGEs)

Non-enzymatic glycation of proteins, lipids, and nucleic acids forms AGEs that crosslink with extracellular matrix (ECM) proteins, stiffening vascular walls and impairing BRB integrity. AGE–RAGE interaction activates NF-κB, enhancing transcription of TNF-α, IL-1β, ICAM-1, and VCAM-1, which drive leukostasis, endothelial apoptosis, and chronic inflammatory damage—culminating in capillary occlusion.

Protein Kinase C (PKC) activation

Excess glucose elevates diacylglycerol (DAG) levels, activating PKC—especially the PKC-β isoform. PKC activation alters endothelial nitric oxide synthase (eNOS) function, decreasing NO bioavailability, promoting vasoconstriction and ischemic hypoxia. PKC further upregulates VEGF and endothelin-1 (ET-1), intensifying vascular permeability and pathological angiogenesis.

Hexosamine pathway

Enhanced glucose flux through the hexosamine biosynthetic pathway results in increased O-GlcNAcylation of transcription factors (e.g., Sp1), leading to upregulation of TGF-β1 and PAI-1. These changes drive extracellular matrix accumulation and basement membrane thickening, worsening retinal ischemia.

Oxidative stress and mitochondrial dysfunction

Oxidative stress is the central pathogenic axis linking metabolic disturbances to structural damage in DR. Hyperglycemia increases mitochondrial electron transport chain flux, generating excess superoxide ($O_2^{\bullet -}$). This causes mitochondrial DNA damage and activates the poly(ADP-ribose) polymerase (PARP) pathway, consuming NAD^+ and ATP, thereby precipitating cellular energy failure and apoptosis in pericytes and neurons. In parallel, NADPH oxidase (NOX2) activation amplifies ROS generation within endothelial and inflammatory cells, leading to endothelial barrier disruption and microvascular rarefaction. Thus, mitochondrial dysfunction and oxidative stress form a self-perpetuating loop accelerating retinal injury.

Inflammation and Leukostasis

Hyperglycemia and hypoxia induce the release of TNF-α, IL-6, IL-8, and MCP-1, activating microglia and recruiting leukocytes to the retinal vasculature. Leukostasis—firm adhesion of leukocytes to endothelium—results in mechanical obstruction, endothelial apoptosis, and localized hypoxia. Sustained NF-κB activation perpetuates inflammation, while complement activation and glial hypertrophy (Müller and astrocytic gliosis) further drive neuroinflammation and neuronal loss.

VEGF Overexpression and pathologic angiogenesis

Ischemic retina stabilizes hypoxia-inducible factor-1α (HIF-1α), which upregulates VEGF-A transcription. VEGF phosphorylates VE-cadherin and reorganizes cytoskeletal actin, increasing vascular permeability. In proliferative DR, uncontrolled VEGF signaling stimulates the formation of fragile neovessels extending into the vitreous cavity, predisposing to hemorrhage and tractional retinal detachment.

Despite its pathogenic role, VEGF also exerts neuroprotective effects, suggesting that anti-VEGF therapies must be balanced to avoid neuronal atrophy.

Neurodegeneration and glial dysfunction

Neurodegeneration precedes visible vascular lesions. Oxidative stress and glutamate toxicity lead to retinal ganglion cell (RGC) apoptosis and synaptic loss. Reactive Müller cells release pro-inflammatory cytokines and excess glutamate, worsening excitotoxicity. Concurrently, decreased neurotrophic factors (BDNF, NGF) exacerbate neuronal vulnerability, reinforcing DR's classification as a neurovascular degenerative disease.

Integrative Model of Disease Progression

DR progression reflects the convergence of metabolic, oxidative, and inflammatory cascades. Early pericyte loss and neuronal dysfunction produce non-proliferative DR with microaneurysms and cotton-wool spots. Worsening ischemia upregulates VEGF, driving proliferative DR and diabetic macular edema (DME)—the principal cause of vision loss.

Hence, DR represents a dynamic continuum where chronic metabolic stress transforms a biochemical disturbance into a complex neurovascular pathology involving intertwined mechanisms of ischemia, inflammation, and neovascularization.

CLINICAL CLASSIFICATION OF DIABETIC RETINOPATHY

The clinical evolution of diabetic retinopathy (DR) reflects a continuum of microvascular and neuroglial damage progressing from early, subclinical changes to advanced, vision-threatening stages. Traditionally, DR is divided into non-proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR), with diabetic macular edema (DME) as a complication that may occur at any stage. Each stage represents a histopathologic correlate of the underlying metabolic and vascular derangements described previously.

Non-Proliferative Diabetic Retinopathy (NPDR)

NPDR represents the earliest clinically detectable stage of DR and is characterized by microaneurysms, intraretinal hemorrhages, and venous abnormalities.

The principal mechanism involves pericyte apoptosis and endothelial cell dysfunction, leading to the formation of acellular capillaries and breakdown of the inner blood-retinal barrier.

These lesions initially occur in the posterior pole, where capillary density and metabolic demand are highest. At the molecular level, severe NPDR reflects diffuse capillary non-perfusion and VEGF upregulation, setting the stage for neovascularization.

Proliferative diabetic retinopathy (PDR)

PDR is defined by pathologic neovascularization arising from the optic disc (NVD) or elsewhere in the retina (NVE), secondary to chronic ischemia and hypoxia.

Hypoxia-inducible factor-1α (HIF-1α) accumulation stimulates VEGF-A transcription, resulting in the proliferation of fragile new vessels lacking proper pericyte coverage.These vessels readily leak plasma proteins and erythrocytes, predisposing to preretinal or vitreous hemorrhage. With progressive fibrovascular proliferation, the newly formed vessels extend along the posterior hyaloid face. Contraction of these fibrovascular membranes generates tractional retinal detachment (TRD), the most severe manifestation of PDR.

Additionally, rubeosis iridis (neovascularization of the iris) and neovascular glaucoma can develop due to VEGF diffusion into the anterior chamber. Histologically, PDR represents an advanced phase of retinal wound-healing gone awry — a pathological attempt to revascularize ischemic tissue through maladaptive angiogenesis.

Diabetic Macular Edema (DME)

DME can occur at any stage of DR and represents the leading cause of visual loss in diabetic patients.

It results from breakdown of both inner and outer blood-retinal barriers, mediated by VEGF, angiopoietin-2, and inflammatory cytokines.

Fluid and plasma proteins accumulate within the macular interstitium, forming cystoid spaces that distort the foveal architecture and impair central vision. Optical coherence tomography (OCT) identifies three structural patterns:

- Focal DME: Localized leakage from microaneurysms.
- Diffuse DME: Widespread capillary leakage and Müller cell swelling.
- Cystoid DME: Coalescence of intraretinal cystic spaces, often accompanied by serous retinal detachment.

Persistent DME induces photoreceptor apoptosis, leading to irreversible visual impairment even after anatomical resolution.

References

1.Chiang JL, Maahs DM, Garvey KC, Hood KK, Laffel LM, Weinzimer SA, Wolfsdorf JI, Schatz D. Type 1 Diabetes in Children and Adolescents: A Position Statement by the American Diabetes Association. Diabetes Care. 2018 Sep;41(9):2026-2044.

2.American Diabetes Association. 13. Children and Adolescents: Standards of Medical Care in Diabetes-2019. Diabetes Care. 2019 Jan;42(Suppl 1):S148-S164

3.Insel RA, Dunne JL, Atkinson MA, Chiang JL, Dabelea D, Gottlieb PA, Greenbaum CJ, Herold KC, Krischer JP, Lernmark Å, Ratner RE, Rewers MJ, Schatz DA, Skyler JS, Sosenko JM, Ziegler AG. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015 Oct;38(10):1964-74.

4.Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet. 2014 Jan 04;383(9911):69-82.

5.Triolo TM, Fouts A, Pyle L, Yu L, Gottlieb PA, Steck AK., Type 1 Diabetes TrialNet Study Group. Identical and Nonidentical Twins: Risk and Factors Involved in Development of Islet Autoimmunity and Type 1 Diabetes. Diabetes Care. 2019 Feb;42(2):192-199.

6.Wolfsdorf JI, Glaser N, Agus M, Fritsch M, Hanas R, Rewers A, Sperling MA, Codner E. ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state. Pediatr Diabetes. 2018 Oct;19 Suppl 27:155-177.

7. Hanas R. Type 1 Diabetes in Children, Adolescents and Young Adults (How to become an expert on your own diabetes). Preface to eighth edition, pages Xİİ, Class Publishing Ltd., London, 2022.

8. Phelan H, King B, Anderson D, Crock P, Lopez P, Smart C. Young children with type 1 diabetes can achieve glycemic targets without hypoglycemia: Results of a novel intensive diabetes management program. Pediatr Diabetes. 2018;19:769-775.

9. Sundberg F, deBeaufort C, Krogvold L, Patton S, Piloya T, Smart C, Van Name M, Weissberg-Benchell J, Silva J, diMeglio LA. ISPAD Clinical Practice Consensus Guidelines 2022: Managing diabetes in preschoolers. Pediatr Diabetes. 2022;23:1496-1511.

10. Annan SF, Higgins LA, Jelleryd E, Hannon T, Rose S, Salis S, Baptista J, Chinchilla P, Marcovecchio ML. ISPAD Clinical Practice Consensus Guidelines 2022: Nutritional management in children and adolescents with diabetes. Pediatr Diabetes. 2022;23:1297-1321. Epub 2022 Dec 5